Last reviewed · How we verify

Routine vaccination of adults 27 years of age and older who have not previously completed the series — Treatment Landscape & Competitive Intelligence

Routine vaccination of adults 27 years of age and older who have not previously completed the series (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Routine vaccination of adults 27 years of age and older who have not previously completed the series, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
MenACWY Vaccine menacwy-vaccine Pfizer Conjugate vaccine Meningococcal antigens

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Routine vaccination of adults 27 years of age and older who have not previously completed the series

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Routine vaccination of adults 27 years of age and older who have not previously completed the series:

Cite this brief

Drug Landscape (2026). Routine vaccination of adults 27 years of age and older who have not previously completed the series — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/routine-vaccination-of-adults-27-years-of-age-and-older-who-have-not-previously-completed-the-series. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing